A real world study investigating effectiveness of single dose oritavancin in patients with skin and skin structure infections by analysing hospitalization and length of stay in US hospitals

Next Previous
Trial Profile

A real world study investigating effectiveness of single dose oritavancin in patients with skin and skin structure infections by analysing hospitalization and length of stay in US hospitals

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Skin and soft tissue infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 24 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top